RECURSION PHARMACEUTICALS, INC. Operating Lease, Expense
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Operating Lease, Expense of $10.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-06-30 was $5.22M, a 7.27% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-03-31 was $5.24M, a 14.47% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-12-31 was $5.23M, a 4.23% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-09-30 was $5.26M, a 5.66% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for fiscal 2025 was $22.25M, a 33.90% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for fiscal 2024 was $16.62M, a 106.08% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for fiscal 2023 was $8.06M, a 4.31% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. operating lease, expense for fiscal 2022 was $7.73M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.46M 10-Q · filed 2026-08-05 | $15.69M derived: sum of 3 quarters · filed 2026-08-05 | $20.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.24M 10-Q · filed 2026-05-06 | $10.47M derived: sum of 2 quarters · filed 2026-05-06 | $15.74M derived: sum of 3 quarters · filed 2026-05-06 | $21.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.49M derived: sum of 2 quarters · filed 2026-02-25 | $16.12M derived: sum of 3 quarters · filed 2026-08-05 | $22.25M 10-K · filed 2026-02-25 |
| 2025-09-30 | $5.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $10.89M derived: sum of 2 quarters · filed 2026-08-05 | $17.02M 10-Q · filed 2025-11-05 | $22.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.76M 10-Q · filed 2026-08-05 | $17.22M derived: sum of 3 quarters · filed 2026-08-05 | $22.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.13M 10-Q · filed 2026-05-06 | $11.59M derived: sum of 2 quarters · filed 2026-05-06 | $17.17M derived: sum of 3 quarters · filed 2026-05-06 | $20.27M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.04M derived: sum of 2 quarters · filed 2026-02-25 | $14.14M derived: sum of 3 quarters · filed 2026-02-25 | $16.62M 10-K · filed 2026-02-25 |
| 2024-09-30 | $5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $8.68M derived: sum of 2 quarters · filed 2025-11-05 | $11.15M 10-Q · filed 2025-11-05 | $13.20M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $5.58M 10-Q · filed 2025-08-05 | $7.62M derived: sum of 3 quarters · filed 2026-02-25 | $9.65M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $2.47M 10-Q · filed 2025-05-05 | $4.52M derived: sum of 2 quarters · filed 2026-02-25 | $6.54M derived: sum of 3 quarters · filed 2026-02-25 | $8.55M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.07M derived: sum of 2 quarters · filed 2026-02-25 | $6.08M derived: sum of 3 quarters · filed 2026-02-25 | $8.06M 10-K · filed 2026-02-25 |
| 2023-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.03M derived: sum of 2 quarters · filed 2024-11-06 | $6.01M 10-Q · filed 2024-11-06 | $8.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.99M 10-Q · filed 2024-08-08 | $5.97M derived: sum of 3 quarters · filed 2025-02-28 | $7.96M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $1.99M 10-Q · filed 2024-05-09 | $3.97M derived: sum of 2 quarters · filed 2025-02-28 | $5.96M derived: sum of 3 quarters · filed 2025-02-28 | $7.98M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $3.97M derived: sum of 2 quarters · filed 2025-02-28 | $5.99M derived: sum of 3 quarters · filed 2025-02-28 | $7.73M 10-K · filed 2025-02-28 |
| 2022-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.00M derived: sum of 2 quarters · filed 2023-11-09 | $5.75M 10-Q · filed 2023-11-09 | $5.75M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $3.76M 10-Q · filed 2023-08-08 | $3.76M derived: sum of 3 quarters · filed 2024-02-29 | $3.76M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $1.74M 10-Q · filed 2023-05-08 | $1.74M derived: sum of 2 quarters · filed 2024-02-29 | $1.74M derived: sum of 3 quarters · filed 2024-02-29 | $474.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | -$1.27M derived: sum of 3 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$1.27M derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.27M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |